Every 424B that 21Shares XRP ETF (TOXR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TOXR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TOXR filings page.
21Shares XRP ETF (symbol TOXR) updates its prospectus to reflect two main changes. First, effective August 27, 2026, the Trust’s NAV and share values are now calculated using the FTSE XRP Index instead of the CME CF XRP–Dollar Reference Rate – New York Variant. The new Pricing Benchmark is a 15‑second VWAP of XRP‑USD prices over a 60‑minute window ending at 4:00 p.m. ET, using filtered executed trades from specified Constituent Exchanges such as Kraken and Bitstamp. The supplement details methodology, exchange eligibility criteria, market‑share data, and risk factors explaining that methodological and venue differences may cause NAV to diverge from what the prior benchmark would have produced.
Second, the Trust clarifies that the 0.30% annual Sponsor Fee still accrues daily based on NAV but is now payable in XRP at least quarterly in arrears, rather than weekly. The Sponsor continues to cover most ordinary operating expenses from this fee. Historical tables compare average, high, low, and end‑of‑period XRP prices under both benchmarks from inception through July 31, 2026, with the Sponsor stating it has not observed material pricing differences over that period.
21Shares XRP ETF (TOXR) filed a prospectus supplement to incorporate a recent current report describing several governance and benchmark changes. The Sponsor, 21Shares US LLC, entered into a Benchmark Licensing Agreement with FTSE International Limited under which the Trust and affiliates receive a non-exclusive worldwide license to use the FTSE XRP Index as the pricing benchmark for the ETF.
Beginning August 27, 2026, the Trust will value its shares and calculate net asset value by reference to this FTSE XRP Index instead of the CME CF XRP-Dollar Reference Rate – New York Variant. The Trust also executed Amendment No. 1 to the Sponsor Agreement to change the Sponsor Fee payment timing from weekly in arrears to at least quarterly in arrears, payable in XRP. A Fourth Amended and Restated Trust Agreement was entered into to reflect the new benchmark, the revised Sponsor Fee timing, and other ministerial and clarifying revisions, which are stated not to materially impact the rights of the Trust or holders of shares.
21Shares XRP ETF reported a sharp contraction in assets as XRP prices fell. Net assets declined from $247.7 million at December 31, 2025 to $112.9 million at June 30, 2026, a 54.41% decrease, driven mainly by a 42.91% drop in XRP from $1.8272 to $1.0431 and net share redemptions.
For the six months ended June 30, 2026, the ETF recorded a net decrease in net assets from operations of $85.2 million, largely from unrealized depreciation on XRP and realized losses on XRP sold to meet redemptions and Sponsor Fees. NAV per share fell from $17.83 to $10.16, with XRP holdings at period-end of 108,256,464.0739 XRP valued at $112.9 million.
The ETF now charges a reduced Sponsor Fee of 0.30% of NAV (previously 2.50% before December 11, 2025), its only recurring expense. The Trust remains an emerging growth company and a grantor trust holding only XRP, so performance is fully concentrated in XRP market movements. Disclosure controls were deemed effective, and there were no material legal proceedings.
21Shares XRP ETF filed a prospectus supplement dated July 7, 2026 that includes a Current Report on Form 8-K reporting a change in benchmark licensing. The Sponsor provided notice terminating the Pricing Benchmark Licensing Agreement with CF Benchmarks, effective August 31, 2026. The Pricing Benchmark (the CME CF XRP—Dollar Reference Rate — New York Variant) has been used to value the Trust's shares and calculate net asset value.
The Sponsor states it intends to enter into a licensing agreement with FTSE International Limited on or about August 24, 2026 to license FTSE index data under a similar one-year, automatically renewing license. The supplement attaches the Form 8-K (without exhibits) and notes both CF Benchmarks and FTSE are unaffiliated with the Sponsor.
21Shares XRP ETF filed a prospectus supplement to attach its latest quarterly report for the period ended September 30, 2025. The ETF is a passive vehicle that holds XRP and trades on Cboe under the ticker TOXR, aiming to track an XRP benchmark in U.S. dollars.
Over the nine months ended September 30, 2025, net assets rose from $209.4 million to $279.9 million, driven mainly by XRP price appreciation. The Trust held 98,120,000 XRP valued at $280.0 million as of September 30, 2025, versus 100,000,000 XRP at year-end 2024, reflecting XRP sold to pay fees.
For the three months ended September 30, 2025, the Trust recorded a net increase in net assets from operations of $54.7 million, with net unrealized gains on XRP of $56.1 million and sponsor fees of $1.8 million. Net asset value per share increased to $27.99, producing total returns at NAV of 24.30% for the quarter and 33.70% for the nine-month period.